Puma Biotech (PBYI) Tops Q4 EPS by 32c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq futures drop over 1% as AI worries resurface, oil climbs
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mail
Get Alerts PBYI Hot Sheet
Join SI Premium – FREE
Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of $0.43, $0.32 better than the analyst estimate of $0.11. Revenue for the quarter came in at $59.1 million versus the consensus estimate of $55.45 million.
For earnings history and earnings-related data on Puma Biotech (PBYI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Procter & Gamble (PG) Tops Q1 EPS by 11c, updates guidance
- Ardagh Metal Packaging S.A. (AMBP) Reports In-Line Q3 EPS
- NASDAQ (NDAQ) Tops Q3 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
